Hims & Hers Health (NYSE:HIMS) Posts Earnings Results, Misses Estimates By $0.32 EPS

Posted by on Aug 10th, 2026

Hims & Hers Health (NYSE:HIMS – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32), FiscalAI reports. The company had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%.

Here are the key takeaways from Hims & Hers Health’s conference call:

  • Revenue and subscriber growth accelerated. Q2 revenue rose nearly 40% year over year to more than $753 million, with 300,000 net new subscribers bringing the total to nearly 3 million; management raised full-year 2026 revenue guidance to $3.1 billion–$3.3 billion.
  • The company reported early benefits from its AI-native care platform, including three times more customer messaging, an approximately 50% reduction in non-clinical support tasks, and lower cancellation rates in pilot cohorts. Management expects AI investments to pay back within 12–18 months and support improved retention and cost efficiency.
  • International expansion is becoming a major growth driver following the Eucalyptus acquisition. International revenue increased more than 17-fold year over year to $131 million, and the company expects international revenue of at least $600 million in 2026 while expanding U.S. specialties such as testosterone, sexual health, and dermatology overseas.
  • New growth opportunities include injectable and oral testosterone before year-end and peptide-related wellness offerings, subject to regulatory developments. The company expects to launch already permitted offerings such as sermorelin, glutathione, and NAD+ by year-end, while awaiting final FDA rulemaking for additional peptides.
  • Profitability and cash flow faced near-term pressure from the business mix and one-time costs. Adjusted gross margin fell to 64% as branded weight-loss products and international revenue grew, Q2 free cash flow was negative $68 million, and the company incurred approximately $81 million in acquisition, restructuring, and FTC-related legal costs; management also said international operations may remain near breakeven as it invests for scale.

Hims & Hers Health Stock Up 0.7%

Shares of NYSE HIMS traded up $0.22 during mid-day trading on Monday, hitting $31.81. The company had a trading volume of 17,006,446 shares, compared to its average volume of 26,837,846. The company has a market capitalization of $7.36 billion, a PE ratio of -353.44, a price-to-earnings-growth ratio of 88.90 and a beta of 2.40. The business’s 50-day simple moving average is $31.86 and its 200 day simple moving average is $26.06. Hims & Hers Health has a 1-year low of $13.74 and a 1-year high of $65.30. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 7,163 shares of the business’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $36.49, for a total value of $261,377.87. Following the completion of the sale, the chief financial officer directly owned 284,321 shares of the company’s stock, valued at $10,374,873.29. The trade was a 2.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David B. Wells acquired 48,400 shares of Hims & Hers Health stock in a transaction on Tuesday, May 26th. The stock was purchased at an average price of $24.23 per share, with a total value of $1,172,732.00. Following the purchase, the director owned 224,417 shares of the company’s stock, valued at $5,437,623.91. The trade was a 27.50% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders sold 83,126 shares of company stock worth $2,711,339. Corporate insiders own 11.76% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors have recently added to or reduced their stakes in HIMS. Binnacle Investments Inc purchased a new stake in shares of Hims & Hers Health during the 3rd quarter worth approximately $28,000. Geneos Wealth Management Inc. acquired a new position in Hims & Hers Health in the first quarter valued at $30,000. Greenline Wealth Management LLC purchased a new position in Hims & Hers Health during the fourth quarter worth about $36,000. DV Equities LLC acquired a new position in Hims & Hers Health during the fourth quarter worth approximately $46,000. Finally, EverSource Wealth Advisors LLC increased its position in Hims & Hers Health by 273.7% during the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after purchasing an additional 687 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on HIMS. Weiss Ratings cut shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research note on Tuesday, May 12th. Citigroup boosted their price objective on Hims & Hers Health from $28.00 to $35.00 and gave the stock a “neutral” rating in a research note on Thursday, July 23rd. JPMorgan Chase & Co. reduced their price target on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Needham & Company LLC upped their price objective on Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and a consensus price target of $31.43.

Read Our Latest Analysis on HIMS

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

  • Positive Sentiment: Second-quarter revenue rose to $753.2 million, surpassing the $698.9 million analyst consensus. The company attributed the performance to strong subscriber growth and broader personalized healthcare offerings. Reuters article
  • Positive Sentiment: Hims & Hers raised its 2026 revenue forecast to $3.1 billion-$3.3 billion from $2.8 billion-$3.0 billion, above the approximately $3.0 billion consensus estimate. Wall Street Journal article
  • Positive Sentiment: Third-quarter revenue guidance of $880 million-$900 million also exceeded the $845.9 million analyst estimate, reinforcing expectations for continued demand and subscriber expansion.
  • Neutral Sentiment: The company said nearly 3 million people rely on its platform, while commentary surrounding the GLP-1 market remains a potential long-term growth catalyst. Company earnings release
  • Negative Sentiment: Hims & Hers reported a quarterly loss of $0.37 per share, missing the $0.05 loss expected by analysts by $0.32. The earnings shortfall appears to be the primary reason the stock has moved lower despite the revenue beat and improved outlook. Benzinga article
  • Negative Sentiment: Several law firms announced investigations into potential securities-law violations or breaches of fiduciary duty related to Hims & Hers. These announcements may add headline risk and increase investor concerns, although no wrongdoing has been established. Scott+Scott investigation

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

Featured Stories

Earnings History for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.